Helisalmi S, Mannermaa A, Lehtovirta M, Ryynänen M, Riekkinen P, Soininen H
Department of Neurology, University Hospital and University of Kuopio, Finland.
Neurosci Lett. 1997 Aug 1;231(1):56-8. doi: 10.1016/s0304-3940(97)00525-9.
Apolipoprotein E (APOE) has been identified as a major susceptibility marker for Alzheimer's disease (AD) and it has been proposed that a common polymorphism in the alpha1-antichymotrypsin (ACT) gene increases the risk of developing AD, when the combination of ACT/AA genotype and APOE epsilon4 allele segregate together. The ACT polymorphism was analysed in 218 sporadic late-onset AD patients and 101 healthy control subjects from Eastern Finland. Samples of the ACT polymorphism were divided into three subgroups according to their APOE genotypes and the genotyping of samples was done using the polymerase chain reaction (PCR) method. Any association between the AD group and the controls was tested with the chi2 test. Our data failed to detect any effect of polymorphism in the ACT genotypes associated with the APOE alleles, suggesting that in this population ACT does not increase the risk of AD.
载脂蛋白E（APOE）已被确定为阿尔茨海默病（AD）的主要易感性标志物，并且有人提出，当α1-抗糜蛋白酶（ACT）基因的一种常见多态性与APOEε4等位基因共同出现时，会增加患AD的风险。对来自芬兰东部的218例散发性晚发型AD患者和101例健康对照者的ACT多态性进行了分析。根据APOE基因型将ACT多态性样本分为三个亚组，并使用聚合酶链反应（PCR）方法对样本进行基因分型。用卡方检验检测AD组与对照组之间的任何关联。我们的数据未能检测到与APOE等位基因相关的ACT基因型多态性的任何影响，这表明在该人群中ACT不会增加患AD的风险。
